CRISPR THERAPEUTICS AG (CRSP) Operating Margin
- Operating margin · 12 months: Value -3989.99%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -3989.99% | Operating income / revenue. Period ending 2026-06-30. $-534.34M ÷ $13.39M × 100 ≈ -3989.99% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -534.34M USD | Operating Income (Loss) |
| Revenue | 13.39M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 278.15M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-534.34M | $13.39M | (m) | $278.15M | (m) | -3989.99% |
| 2026-03-31 | $-646.39M | $4.10M | (m) | $280.90M | (m) | -15754.20% |
| 2025-12-31 | $-664.57M | $3.51M | (m) | $284.81M | (m) | -18933.65% |
| 2025-09-30 | $-574.39M | $38.34M | (m) | $283.44M | (m) | -1498.28% |
| 2025-06-30 | $-552.47M | $38.05M | (m) | $306.69M | (m) | -1451.95% |
| 2025-03-31 | $-474.40M | $37.67M | (m) | $316.96M | (m) | -1259.20% |
| 2024-12-31 | $-466.57M | $37.31M | (m) | $320.65M | (m) | -1250.38% |
| 2024-09-30 | $-332.39M | $202.83M | (m) | $333.64M | (m) | -163.88% |
| 2024-06-30 | $-354.68M | $202.23M | (m) | $342.18M | (m) | -175.39% |
| 2024-03-31 | $-298.64M | $271.71M | (m) | $363.57M | (m) | -109.91% |
| 2023-12-31 | $-222.54M | $371.21M | (m) | $387.33M | (m) | -59.95% |
| 2023-09-30 | $-423.66M | $170.01M | (m) | $395.74M | (m) | -249.20% |
| 2023-06-30 | $-473.64M | $170.10M | (m) | $421.67M | (m) | -278.45% |
| 2023-03-31 | $-561.68M | $100.26M | (m) | $443.33M | (m) | -560.23% |
| 2022-12-31 | $-673.16M | $1.20M | (m) | $461.64M | (m) | -56190.40% |
| 2022-09-30 | $-687.32M | $14.09M | (m) | $559.25M | (m) | -4877.71% |
| 2022-06-30 | $-633.78M | $14.82M | (m) | $526.13M | (m) | -4276.22% |
| 2022-03-31 | $312.10M | $915.36M | (m) | $486.26M | (m) | 34.10% |
| 2021-12-31 | $373.53M | $914.96M | (m) | $438.63M | (m) | 40.82% |
| 2021-09-30 | $411.46M | $902.43M | (m) | $386.53M | (m) | 45.60% |
| 2021-06-30 | $447.92M | $901.76M | (m) | $352.21M | (m) | 49.67% |
| 2021-03-31 | $-395.39M | $1.10M | (m) | $303.32M | (m) | -35912.08% |
| 2020-12-31 | $-354.44M | $719.00K | (m) | $266.95M | (m) | -49295.55% |
| 2020-09-30 | $-235.69M | $77.36M | (m) | $233.34M | (m) | -304.65% |
| 2020-06-30 | $-4.13M | $289.14M | (m) | $219.58M | (m) | -1.43% |
| 2020-03-31 | $21.58M | $289.42M | (m) | $199.73M | (m) | 7.46% |
| 2019-12-31 | $46.74M | $289.59M | (m) | $179.36M | (m) | 16.14% |
| 2019-09-30 | $-9.47M | $212.69M | (m) | $159.40M | (m) | -4.45% |
| 2019-06-30 | $-198.07M | $1.32M | (m) | $141.98M | (m) | -14959.67% |
| 2019-03-31 | $-180.37M | $2.09M | (m) | $128.08M | (m) | -8613.61% |
| 2018-12-31 | $-158.94M | $3.12M | (m) | $113.77M | (m) | -5087.80% |
| 2018-09-30 | $-112.74M | $35.33M | (m) | $105.00M | (m) | -319.08% |
| 2018-06-30 | $-86.88M | $37.16M | (m) | $83.03M | (m) | -233.82% |
| 2018-03-31 | $-70.90M | $39.65M | (m) | $74.51M | (m) | -178.81% |
| 2017-12-31 | $-64.65M | $41.00M | (m) | $69.80M | (m) | -157.69% |
| 2017-09-30 | $-90.93M | $11.02M | (m) | $65.34M | (m) | -825.44% |
| 2017-06-30 | $-81.97M | $10.18M | (m) | $59.55M | (m) | -805.36% |
| 2017-03-31 | $-77.22M | $7.39M | (m) | $51.03M | (m) | -1044.81% |
| 2016-12-31 | $-68.13M | $5.16M | (m) | $42.24M | (m) | -1319.33% |
| 2016-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $-46.58M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $-33.65M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $-25.73M | $247.00K | (m) | $12.57M | (m) | -10416.60% |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $-6.63M | (m) | (m) | $1.51M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |